Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Cartesian Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -10518.6%. For fiscal 2025 it was -5127.1%, against -112.8% the year before. The highest annual figure on record is 13.1% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5127.1% | −5014.3 |
| FY2024 | Dec 31, 2024 | -112.8% | +219.5 |
| FY2023 | Dec 31, 2023 | -332.3% | −345.4 |
| FY2022 | Dec 31, 2022 | 13.1% | +18.5 |
| FY2021 | Dec 31, 2021 | -5.4% | +337.0 |
| FY2020 | Dec 31, 2020 | -342.4% | +443.3 |
| FY2019 | Dec 31, 2019 | -785.6% | +6415.1 |
| FY2018 | Dec 31, 2018 | -7200.7% | +23612.9 |
| FY2017 | Dec 31, 2017 | -30813.5% | −30384.6 |
| FY2016 | Dec 31, 2016 | -428.9% | −8.0 |
| FY2015 | Dec 31, 2015 | -421.0% | +85.6 |
| FY2014 | Dec 31, 2014 | -506.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -33973.1% | −31983.2 |
| Q4 FY2025 | Dec 31, 2025 | -8304.0% | −3762.7 |
| Q3 FY2025 | Sep 30, 2025 | -4660.6% | −4701.8 |
| Q2 FY2025 | Jun 30, 2025 | -7319.1% | −7090.6 |
| Q1 FY2025 | Mar 31, 2025 | -1989.9% | −1550.4 |
| Q3 FY2024 | Sep 30, 2024 | -4541.3% | −4341.9 |
| Q2 FY2024 | Jun 30, 2024 | 41.1% | +396.2 |
| Q1 FY2024 | Mar 31, 2024 | -228.6% | +81.0 |
| Q4 FY2023 | Dec 31, 2023 | -439.5% | −388.9 |
| Q3 FY2023 | Sep 30, 2023 | -199.4% | −191.7 |
| Q2 FY2023 | Jun 30, 2023 | -355.1% | −390.4 |
| Q1 FY2023 | Mar 31, 2023 | -309.5% | −341.2 |
| Q4 FY2022 | Dec 31, 2022 | -50.6% | −64.2 |
| Q3 FY2022 | Sep 30, 2022 | -7.7% | +0.3 |
| Q2 FY2022 | Jun 30, 2022 | 35.3% | +33.0 |
| Q1 FY2022 | Mar 31, 2022 | 31.7% | +96.5 |
| Q4 FY2021 | Dec 31, 2021 | 13.6% | +79.7 |
| Q3 FY2021 | Sep 30, 2021 | -8.1% | +287.5 |
| Q2 FY2021 | Jun 30, 2021 | 2.3% | +191.2 |
| Q1 FY2021 | Mar 31, 2021 | -64.8% | +124819.8 |
| Q4 FY2020 | Dec 31, 2020 | -66.1% | +118493.9 |
| Q3 FY2020 | Sep 30, 2020 | -295.6% | +1310.0 |
| Q4 FY2019 | Dec 31, 2019 | -188.9% | +113205.2 |
| Q2 FY2019 | Jun 30, 2019 | -124884.6% | −73573.5 |
| Q1 FY2019 | Mar 31, 2019 | -118560.0% | −57517.7 |
| Q4 FY2018 | Dec 31, 2018 | -1605.6% | +9184.1 |
| Q4 FY2017 | Dec 31, 2017 | -113394.1% | −112921.1 |
| Q3 FY2017 | Sep 30, 2017 | -51311.1% | −50598.5 |
| Q2 FY2017 | Jun 30, 2017 | -61042.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -10789.8% | – |
| Q4 FY2016 | Dec 31, 2016 | -473.0% | – |
| Q3 FY2016 | Sep 30, 2016 | -712.6% | – |
See a number that looks wrong?